PURPOSE:
The primary objective is to evaluate the efficacy and safety of RSO-021 in participants with Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma.
Have this trial number available
NCT05278975
US NIH: clinicaltrials.gov
DATES: Starts: March 31, 2022 | Ends: April 1, 2025
US NIH: clinicaltrials.gov NCT05278975
Mesothelioma UK: mesothelioma.uk.com or call
Freephone: 0800 169 2409
NIHR UK: bepartofresearch.nihr.ac.uk
MITOPE is sponsored by RS Oncology, LLC
Eligibility
MPE
Diagnosed with Malignant Pleural Effusion due to metastatic disease or mesothelioma
IPC
Has IPC installed or is a good candidate for IPC installation
Performance
Status
Has ECOG PS < 1
Accepting Patient Referrals
By choosing to participate in the Mitope clinical trial, patients will have access to novel therapies, that has the potential to be more effective than standard treatments and contribute to research for the future. Professional healthcare providers can refer patients by contacting us mitope@rsoncology.com
MITOPE Locations
